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Abstract
Background: Trans-arterial radio-embolization (TARE) is an emerging treatment for the management of hepatocellular
carcinoma (HCC). TARE may compete with systemic chemotherapy, sorafenib, in intermediate stage patients with prior
chemoembolization failure or advanced patients with tumoral macrovascular invasion with no extra-hepatic spread
and good liver function.
We performed a budget impact analysis (BIA) evaluating the expected changes in the expenditure for the Italian
Healthcare Service within scenarios of increased utilization of TARE in place of sorafenib over the next five years.
Methods: Starting from patient level data from three oncology centres in Italy, a Markov model was developed to
project on a lifetime horizon survivals and costs associated to matched cohorts of intermediate-advanced HCC patients
treated with TARE or sorafenib. The initial model has been integrated with epidemiological data to perform a BIA
comparing the current scenario with 20 and 80% utilization rates for TARE and sorafenib, respectively, with increasing
utilization rates of TARE of 30, 40 and 50% over the next 1, 3 and 5 years.
Results: Compared to the current scenario, progressively increasing utilization rates of TARE over sorafenib in the next
5 years is expected to save globally about 7 million Euros.
Conclusions: Radioembolization can be considered a valuable treatment option for patients with intermediate-
advanced HCC. These findings enrich the evidence about the economic sustainability of TARE in comparison to
standard systemic chemotherapy within the context of a national healthcare service.
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Background
Liver cancer is one of the most frequent cancers in the
world, with a 5-year prevalence of 633,000 cases, 782,000
new diagnoses in 2012, causing more than 700,000 deaths
globally per annum [1]. Hepatocellular carcinoma (HCC)
is the most frequent type of liver cancer, accounting for
90% of all liver cancers [2].
In order to guide the therapeutic approach and to pre-
dict the prognosis of patients with HCC, different staging
systems are used. The BCLC (Barcelona-Clinic Liver
Cancer) classification is considered the standard system
by the American Association of for the Study of Liver Dis-
ease (AASLD) [3] and European Association for the Study
of the Liver [4]. The system identifies patients with early
HCC (stage 0 and A), intermediate (stage B) or advanced
stage (stage C) and those with very poor life expectancy
(stage D).
Treatment schedules are recommended for each stage,
ranging from curative therapies, such as resection or
transplant for early stage patients, to best supportive
care for terminal patients.
Intra-arterial transcatheter embolotherapies are rec-
ommended for non-surgical patients in the intermediate
HCC stage, while sorafenib is the standard systemic
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herapy for patients with advanced HCC and
well-preserved liver function and those with
intermediate-stage HCC who progress following
trans-arterial chemoembolization (TACE). However, in a
sub-analysis of trials involving sorafenib, the tolerability
of this treatment resulted suboptimal [5]. This situation
opened the way to new therapies for the management of
intermediate or advanced-stage HCC and, in this setting,
transarterial radioembolization (TARE) showed to be a
valuable therapeutic option [6–10].
TARE is one type of intra-arterial brachytherapy used
to treat HCC. TARE is performed using glass (Thera-
Sphere®, MDS Nordion Inc.) or resin (SIR-Spheres®, Sir-
tex Medical Inc.) microspheres including β-emitter Y-90.
The potential clinical benefits of TARE for the treatment
of HCC are under investigation. Its organizational and
economic impacts should also be carefully evaluated as
TARE is a complex and expensive intervention.
One of the main issues in the evaluation of the
cost-effectiveness of locoregional treatments for HCC is
the lack of published randomized clinical trials’ results. De-
cision models may help filling this gap since they allow
pooling information from different sources to perform
cost-effectiveness analyses. In the literature few studies
using this approach are reported. Chaplin and colleagues
[11] performed a cost-effectiveness analysis of TARE com-
pared to sorafenib for the treatment of HCC in the UK.
The study showed that TARE yielded a total lifetime cost
lower than sorafenib (£21,441 vs. £34,050) with a quality
adjusted life year (QALY) gain of 0.27 (TARE dominant).
Another study assessed the cost-effectiveness of TARE in
comparison to conventional transarterial chemoemboliza-
tion in the United States [12], showing lifetime costs of
$31,000 and $48,000 for unilobar and bilobar radioemboli-
zation, respectively. For advanced stage patients, the incre-
mental cost-effectiveness ratio of TARE versus TACE
resulted 360$ per month (3120$ per year). A more recent
study performed in Italy [13] reported for intermediate
stage patients an incremental cost-utility ratio (ICUR) for
TARE vs. sorafenib of 3302€/QALY, whilst for advanced
stage patients, TARE seemed to be a dominant strategy
(lower costs and greater health improvements) compared
to sorafenib.
But what does this evidence bring to the financial pros-
pects of the national healthcare budget? Although few
studies assessed the cost-effectiveness of TARE in com-
parison to other locoregional or systemic treatments, the
budget impact analysis (BIA) of the introduction of this
technology at national level is still unexplored. The BIA is
an essential component of a complete economic assess-
ment of health technologies aiming at estimating the fi-
nancial consequences, in the short-medium term, on the
total healthcare national budget derived from the diffusion
of a new therapeutic intervention, in combination with
treatments already used for the management of a particu-
lar disease within a specific healthcare system [14].
The cost-effectiveness model developed by Rognoni et al.
[13] has been applied to perform a BIA considering increas-
ing utilization rates of TARE in place of sorafenib for the
treatment of intermediate-advanced stage HCC patients in
the Italian healthcare system over a 5-years horizon.
Methods
Markov model
Patient level data were collected at three Italian oncology
centers which have performed TARE procedures since
2005: National Cancer Institute, Milan (288 TARE and
125 sorafenib patients); Azienda Ospedaliero-Universitaria
Pisana, Pisa (38 TARE and 42 sorafenib patients); Azienda
Ospedaliero-Universitaria, Bologna, Policlinico S.Orsola-
Malpighi, Bologna (63 TARE and 74 sorafenib patients).
A propensity score matching procedure was performed
to obtain two sets of patients, treated with TARE (154
patients) or sorafenib (154 patients), with similar clinical
characteristics in terms of Child-Pugh Score, number of
nodules (one nodule vs. multinodular) and presence/ab-
sence of portal vein thrombosis (PVT). Additional file 1:
Table S1 reports the patients’ clinical characteristics
before and after the matching.
A Markov model was developed to project, on a
lifetime horizon, survivals and costs associated to the
matched cohorts of intermediate-advanced HCC
patients treated with TARE or sorafenib. The health
states considered were stable disease, disease progres-
sion and death. In the intermediate stage an additional
state was included to take into account the possibility
of liver transplantation (Fig. 1). A hypothetical cohort
of HCC patients enters the Markov process in the
stable disease state, i.e. with stable HCC. A focus group
with seven expert physicians from the three oncology
centers was organized to get their advice on the model
structure and validation.
Transition probabilities among different health
states were derived from overall survival and
progression-free survival curves calculated from the
matched cohorts (see Additional file 2: Figure S1). In
order to adopt the lifetime horizon in the health eco-
nomic evaluation, as suggested by NICE [15], original
Kaplan-Meier curves were fitted by analytic functions.
In the final matched cohorts, intermediate stage
patients undergoing TARE (71%) and sorafenib (49%)
reported mean survivals of 24.0 months (median 18.5)
and 18.4 months (median 13.0), respectively. In the
group of advanced stage patients (29% TARE and 51%
sorafenib) these values decreased respectively to
14.9 months (median 11.2) and 16.1 (median 11.3)
months.
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Healthcare resources consumption and costs
The analysis was performed from the Italian Healthcare
Service perspective and only healthcare costs (€, 2018) in-
curred by the Healthcare Service were considered. Given
the decentralized nature of the Italian healthcare system,
with 19 Regions and 2 Autonomous Provinces, for the
scope of the present study we referred to costs and tariffs
from Lombardy Region, which is the region with the high-
est DRG reimbursement for TARE. This choice allows for
conservative estimates of the hypothetical savings at na-
tional level once and if the diffusion of this innovative
technology takes place in the clinical practice.
Treatment protocols for TARE and sorafenib were
identified through discussions with focus group mem-
bers. TARE protocol includes a first oncology visit, a
procedure simulation (DRG 203), lab exams, and the
treatment itself. Admissions for brachytherapy or radio-
embolization therapies for malignant hepatocellular car-
cinoma refer to “DRG 409 - Radiotherapy”, with an
increased tariff in order to recover the costs related to
the microspheres, the interventional radiology procedure
and the necessary hospitalization days.
After one month, oncology visit and lab exams are re-
peated, including an abdomen computed tomography
(CT) examination. The follow-up phase includes an on-
cology visit, lab exams and an abdomen CT examination
every three months [16].
The mean number of TARE treatments per patient re-
sulted 1.1 and 1.02 for intermediate and advanced stages,
respectively.
Sorafenib is generally delivered monthly (112 cp
200 mg each, hospital cost 3536.17€), after an oncology
visit and lab exams, to each patient until disease pro-
gression. A payment-by-result scheme is adopted in Italy
whereby for each non-responder in the first two months,
the drug manufacturer refunds the sustained initial
treatment cost (max 2 packages). In order to verify the
state of the disease, an abdomen CT examination is per-
formed after two months of treatment with sorafenib,
while the rest of the follow-up is the same as for TARE.
The mean duration of sorafenib treatment resulted 7.5
and 8.1 months for intermediate and advanced stages,
respectively.
Second-line treatments were identified from the
matched databases and were included in the model. Liver
decompensation was acknowledged by the focus group as
the leading side effect, taking into account both economic
and clinical aspects. It was assumed that liver decompen-
sation happens in the first year of treatment leading al-
ways to hospitalization. As regards liver transplantation,
the cost was estimated through the DRG reimbursement
tariff, while the yearly cost after the intervention was de-
rived from a study by Cammà and colleagues [17] and in-
flated to year 2018 using the Italian Consumer Price Index
(ITCPI 2005) [18]. All cost components used in the model
are summarized in Table 1.
Budget impact analysis
In order to evaluate the expected changes in the expend-
iture for the Italian Healthcare Service in the hypothesis
of an increased utilization of TARE in place of sorafenib, a
budget impact model was built based on the initial Mar-
kov model. The analysis was conducted in accordance
with the ISPOR Principles of Good Practice for Budget
Impact Analysis [14]. The Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist [19]
is reported in the Additional file 3: Appendix.
The model has been developed according to the
following steps:
1. Research and analysis of epidemiological data (i.e.
incidence) relating to patients with intermediate-
advanced stage HCC in Italy, eligible to either
TARE or sorafenib,
Fig. 1 Markov model. A hypothetical cohort of 68-year-old (i.e. mean age of the matched population) HCC patients enter the Markov process in
the stable disease state, i.e. with stable HCC
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Table 1 Healthcare resources and costs used in the model (visits and exams refer to both TARE and sorafenib treatments)
Exam/procedure/DRG Timing Code Cost (€) Reference
CT examination (abdomen) every 3 months 88.01.5 137.23 Regional Healthcare Service
price list
First visit 1 time 89.7B.6 22.50 Regional Healthcare Service
price list
Control visit every 3 months 89.01.F 17.90 Regional Healthcare Service
price list
Blood count every 3 months 90.62.2 4.05 Regional Healthcare Service
price list
Creatinine every 3 months 90.16.3 1.70 Regional Healthcare Service
price list
Sodium every 3 months 90.40.4 1.70 Regional Healthcare Service
price list
Potassium every 3 months 90.37.4 1.70 Regional Healthcare Service
price list
Calcium every 3 months 90.11.4 1.70 Regional Healthcare Service
price list
Prothrombin time every 3 months 90.75.4 2.60 Regional Healthcare Service
price list
Albumin every 3 months 90.05.1 2.90 Regional Healthcare Service
price list
Bilirubin every 3 months 90.10.4 1.70 Regional Healthcare Service
price list
Alpha-Fetoprotein every 3 months 90.05.5 11.05 Regional Healthcare Service
price list
Alanine amino transferase (alt) (gpt) every 3 months 90.04.5 1.70 Regional Healthcare Service
price list
Gamma-glutamyl transpeptidase every 3 months 90.25.5 1.70 Regional Healthcare Service
price list
Alkaline phosphatase every 3 months 90.23.5 1.70 Regional Healthcare Service
price list
Sorafenib 7.5 and 8.1 months duration for intermediate
and advanced stages, respectively.
Following TARE: 30.3% of patients in intermediate
stage, 20% of patients in advanced stage
3787 Monthly Hospital cost
TARE simulation 1 procedure per patient 203 4052 Regional DRG reimbursement
TARE 1.1 procedures per patient in intermediate stage,
1.02 procedures per patient in advanced stage
409 9510 Regional DRG reimbursement
TACE Following TARE: 18.3% of patients in intermediate
stage, 2.2% of patients in advanced stage;
Following Sorafenib: 6.6% of patients in intermediate
stage, 2.6% of patients in advanced stage
203 4052 Regional DRG reimbursement
RFA/PEI or liver resection Following TARE: 5.5% in intermediate stage;
Following Sorafenib: 10.5% of patients in
intermediate stage, 1.3% of patients in advanced
stage
192 7549 Regional DRG reimbursement
Radiotherapy Following TARE: 2.2% in advanced stage 409 4041 Regional DRG reimbursement
Hospitalization for liver decompensation TARE: 19.4% of patients in intermediate stage,
43% of patients in advanced stage;
Sorafenib: in intermediate stage 17.4%, in
advanced stage 31%
464 1688 Regional DRG reimbursement
Liver transplantation Following TARE: 3.7% of patients in intermediate
stage
480 68,027 Regional DRG reimbursement
Liver transplantation (yearly
cost after intervention)
Following TARE: 3.7% of patients in intermediate
stage
6229 Cammà 2013 [17], uplifted to
year 2018
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2. Definition of the current scenario of distribution of
patients among the two alternative therapeutic
approaches,
3. Definition of future scenarios with appropriate
increased use of TARE over sorafenib, considering
different annual penetration rates.
The annual incidence of liver carcinoma in Italy ac-
counts for about 13,200 patients [20], of which about
75% can be considered HCCs [21]. Of these, 45.4%
(14.9% intermediate + 30.5% advanced) are intermediate
or advanced stage tumors according to ITALICA (ITAl-
ian LIver CAncer) database [22].
The counts of intermediate-advanced HCC patients eli-
gible for TARE or sorafenib have been estimated from the
ITALICA database taking into account: intermediate stage
patients treated with sorafenib (9.5%) and advanced stage
patients treated with TACE (28.8%). All together, these
account for 10.2% of HCC patients eligible for TARE or
sorafenib, that is 1010 intermediate-advanced patients per
year in Italy (i.e. 140 intermediate stage and 870 advanced
stage).
The current scenario of patients’ distribution between
the two alternative treatments was estimated from the
ITALICA database as well. Between 2010 and 2014, the
registry reported prescription of sorafenib in 9.3% of cases
and administration of other treatments (TARE) in 2.1% of
cases, therefore the resulting utilization rates of TARE and
sorafenib were about 20 and 80%, respectively.
In order to estimate the prevalent patients population
(cohort of alive patients) treated with TARE or sorafenib
in the current scenario, a simulation was performed using
the Markov model, by considering yearly incident cohorts
of 1010 patients (140 intermediate stage and 870 advanced
stage). A steady prevalent population of 1019 patients re-
sulted considering 20 yearly incident cohorts. In the
current scenario the majority of patients (86%) is in the
advanced stage and is treated with sorafenib; advanced
HCC patients undergoing systemic chemotherapy have a
median survival of about 1 year (see Additional file 1:
Table S1) and this is the reason why prevalence (1019 pa-
tients) and incidence (1010 patients) are similar.
Future scenarios, in which reasonable increased pro-
portions of TARE over sorafenib are considered, were
recommended by the focus group as 30, 40 and 50% for
1-year, 3 years and 5-years horizon, respectively. The
model applies the variations of the market share to the
new incident cohorts (naive treatments), without involv-
ing the prevalent cohorts in the variations. Constant in-
cident cohorts were considered in the analysis.
The costs for current and future scenarios were esti-
mated by multiplying yearly costs of each option by the
proportion of the eligible population using that option
and by the number of patients in the eligible population,
taking into account baseline prevalent patients and sub-
sequent yearly incident cohorts. As the focus was on the
expected budget at each point in time, the financial
streams were presented as undiscounted costs [14].
The flexibility of the model chosen allowed for add-
itional analyses. A number of scenario analyses have been
performed to test the robustness of the Markov model re-
sults on a lifetime horizon [13]. As the mean number of
TARE procedures per patient (from 1 to 3) and sorafenib
cost resulted as parameters highly affecting ICER varia-
tions [13], budget impact scenario analyses were therefore
performed considering 1.5 TARE per patient as reported
by [23], and halved sorafenib cost. Moreover, considering
increased uses of TARE in the next years, the number of
deaths avoided and the number of hospitalizations due to
liver decompensation have been estimated.
Results
Budget impact analysis
In the intermediate stage, a mean lifetime cost (undis-
counted) per patient of 33,040€ (std. dev. 32,766€) and
29,935€ (std. dev. 29,410€) for TARE and sorafenib regi-
mens, respectively, was estimated. These values changed
to 22,526€ (std. dev. 11,249€) and 31,526€ (std. dev.
30,930€) for advanced stage patients. These costs include
the cost for the treatment itself (TARE or sorafenib), for
control visits and examinations, subsequent treatments
and for the management of adverse events (liver decom-
pensation). When considering a time horizon of 5 years,
in the intermediate stage, costs per patient of 28,003€
(std. dev. 18,217€) and 29,716€ (std. dev. 29,254€) were
obtained for TARE and sorafenib regimens, respectively,
leading to an incremental cost of 1713€. For advanced
stage patients, these values changed to 21,456€ (std. dev.
7399€) and 31,430€ (std. dev. 30,338€), respectively,
leading to an incremental cost of 9974€.
Detailed yearly costs by categories are reported in
Additional file 4: Table S2.
The financial impact on the national healthcare budget
after increasing TARE utilization for patients with
intermediate-advanced HCC stage was studied. The yearly
total cost for TARE and sorafenib treatment mix is pre-
sented in Fig. 2. According to the hypothesis that the
population is mainly composed by individuals with ad-
vanced stage disease and for these patients the cost for
TARE is lower in comparison to sorafenib, the first most
important observation is that the total budget decreases
over time according to the increased use of radioemboli-
zation. In comparison to the current scenario (year 0), by
progressively increasing TARE utilization rates to 30, 40
and 50%, it would be possible to save 506,121€, 899,993€,
1,453,861€, 1,827,536€ and 2,345,636€ for 1, 2, 3, 4 and
5-year scenarios, respectively, yielding total savings of
about 7 million Euros.
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Figure 3 reports, for each year, the number of deaths
avoided starting from the current scenario and consider-
ing increased uses of TARE in the following years. A
time horizon of 10 years has also been investigated for
these analyses on expected impact on outcomes to ac-
count for the achievement of a “steady state” (with 50%
TARE and 50% sorafenib utilization rates from year 5
onwards). As reported in Fig. 3, two is the number of
avoided deaths reached at 5 years, but this value in-
creases to fourteen at ten years, when the utilization rate
of TARE is maintained at 50%. Using the same approach,
Fig. 4 reports the number of additional hospitalizations
due to liver decompensation considering increased uses
of TARE in the next years. The increase in the number
of hospitalizations is due to the higher frequency of liver
decompensation for both intermediate and advanced
stage patients undergoing TARE in comparison to soraf-
enib. As described previously, the difference in number
of hospitalizations reaches the steady number of 32 from
year 5 onwards, when the utilization rates are main-
tained at 50% for TARE and 50% for sorafenib.
The scenario analysis performed considering a mean
number of TARE per patient equal to 1.5 for both
intermediate and advanced stages, instead of 1.1 and
1.02, showed total savings of about 1,150,000€ instead of
about 7 million Euros. When considering halved sorafe-
nib cost, the analysis led to a total additional cost of
about 4,800,000€ over the next five years.
Discussion
HCC is a life-threatening disease. Despite considerable im-
provements in the diagnoses and treatments, the available
cure options are only partially effective [24] and the disease
is very difficult to control when presenting in the advanced
stage [3, 25]. Within a resource-limited healthcare system,
this context highlights the need for resources to be used ef-
ficiently in order to guarantee the best outcomes to this
population.
Real world clinical data of two cohorts of patients,
treated with TARE or sorafenib, matched according to
Child-Pugh score, presence or absence of PVT and num-
ber of nodules, were used to populate a model in order to
estimate lifetime costs and health outcomes. In the final
matched cohorts, intermediate stage patients undergoing
TARE and sorafenib yielded mean survivals of 24.0 (me-
dian 18.5) and 18.4 months (median 13.0), respectively. In
Fig. 2 Budget impact for the Italian Healthcare Service considering increasing uses of TARE in the next years
Fig. 3 Estimated number of deaths per year for current and future scenarios
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the group of advanced stage patients these values de-
creased respectively to 14.9 (median 11.2) and 16.1 (me-
dian 11.3) months. Patients’ survivals in the TARE group
appear lower than other published figures data [9, 26, 27].
The propensity score matching selected pairs of patients
with similar clinical characteristics, eligible indifferently to
TARE or sorafenib treatments, favoring the selection of
patients in worse clinical conditions and, indeed, with
lower life expectancy. As regards the costs, the evaluation
focused on first-line treatments, control visits and exami-
nations, management of side effects (liver decompensa-
tion) and subsequent treatments (second line treatments
after TARE or sorafenib).
The budget impact analysis showed that the Italian
Healthcare Service could save about 7 million Euros in
the hypothesis of an increased utilization of TARE, from
20 to 50%, in place of sorafenib in the next 5 years. The
model robustness has already been tested performing a
number of sensitivity analyses [13], however, two scenario
budget impact analyses showed reduced savings (about
1,150,000€) in case of 1.5 TARE treatments performed per
patient or an increase in the national healthcare budget
(about 4,800,000€) in case of halved sorafenib cost. It
should be noted that these scenarios are unlikely to be
representative of the actual practice but can give informa-
tion on the budget variations in extreme cases.
Budget impact analysis is an important component of
the economic evaluation of healthcare interventions,
which is gaining significant relevance in formal health
technology assessment systems in place across several
jurisdictions and certainly in Italy. This is the first study
estimating the impact on the Italian healthcare budget of
TARE and sorafenib strategies in intermediate-advanced
stage HCC patients. A previous study tried to evaluate
the patterns of treatment and costs related to HCC
treatments, reporting an overall expenditure of 12,215€
for sorafenib and 26,106€ for TARE patients per year.
However that analysis was performed from the hospital
perspective and based on structured interviews with
physicians in four Italian centers [23]. Another study
[28], presented the results of a BIA from a hospital per-
spective in Canada. This study showed that, for a hos-
pital managing 200 HCC patients annually, an increased
use of TARE over TACE and sorafenib could incur sav-
ings of approximately $37,000, $55,000 and $75,000 in
years 1, 2 and 3, respectively.
This study has some limitations. First of all, costs were
estimated from the Lombardy Region perspective, and
then considered as a proxy for the other Italian Regions.
In a decentralized system such as the Italian NHS, one
should consider separately each different Region to en-
tirely capture all the specific features of the healthcare
service provision and costs [29]. However, most of Ital-
ian Regions performing TARE have a special DRG reim-
bursement rate according to the use of Y-90
microspheres (DRG 409) and in these regions TARE re-
imbursement tariffs are quite similar (e.g. 8500€ for Emi-
lia Romagna, 8568€ for Piedmont, 9510€ for Lombardy)
meaning that the model could be considered reasonably
conservative in this respect. Moreover, the healthcare re-
source consumption has been expressed in natural units
(Table 1), as suggested by EunetHTA [30], to allow the
model extension to other countries. Furthermore, the
budget impact does not take into account the sunk costs
of setting up the TARE procedure in a new organization.
However, provided the angiographic room and imaging
equipment are already available, these costs will refer
mainly to a thorough training of the staff [31].
The consumption of healthcare resources has been re-
trieved from clinical data only for cancer related therapies
(i.e. duration of treatment with sorafenib, mean number of
TARE treatments per patient and subsequent treatments)
Fig. 4 Estimated number of hospitalizations for liver decompensation per year for current and future scenarios
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while a predefined schedule, although validated by the focus
group, for visits and examinations was applied for the
follow-up period. This approach might have underesti-
mated the real healthcare resource consumption. Analysis
of data on best supportive care offered to patients after
treatment failure resulted mainly in the use of off-label
drugs or chemotherapy, with no reported indication of dose
and duration, and an evaluation including this aspect was
not possible. Even though liver decompensation was
highlighted by the focus group as the main and most ex-
pensive adverse effect caused by TARE or sorafenib, other
adverse events could have an impact on both costs and
patient’s quality of life. More data on the occurrence of
other side effects would allow for a more comprehensive
evaluation.
As regards epidemiological data on prevalence and
incidence of HCC in intermediate and advanced eli-
gible for TARE and sorafenib therapies, as well as the
current mix of treatment strategies in the eligible
population, we relied on the largest source in Italy,
the ITALICA registry, reporting data updated to 2014.
Considering that TARE is an emerging treatment
showing a promising efficacy in terms of disease con-
trol with a good safety profile [32], it is likely that its
diffusion has been underestimated. In this regard, the
results shown may have overestimated the potential
savings due to the diffusion of this advanced medical
device technology occurred since the last update of
the ITALICA registry (2014).
Conclusions
Radioembolization can be considered a valid treatment
option, giving an “additional” chance of survival for pa-
tients with intermediate-advanced hepatocellular carcin-
oma. The attitude towards this type of treatment is usually
positive, while eventual side effects are considered toler-
able. The present study adds evidence about the economic
sustainability of TARE in comparison to standard systemic
chemotherapy, sorafenib, at national level, showing that a
decrease of the Italian healthcare budget is possible
through an increase of the diffusion of this advanced med-
ical device technology. Further prospective studies and in-
creased awareness around the cost-effectiveness profile of
healthcare technologies in this area will be able to provide
additional data to confirm our conclusions.
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